Vectorite Biomedical, Inc.

As of June 30, 2026, Vectorite Biomedical, Inc. carries a market capitalization of 544.95M, placing it among publicly traded companies globally. Its enterprise value stands at 379.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vectorite Biomedical, Inc. has 43.77M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Vectorite Biomedical, Inc. maintains a current ratio of 10.05, meaning it holds 10.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Vectorite Biomedical, Inc.'s stock has declined approximately 16.96% over the past 52 weeks. The 50-day moving average sits at 12.49, while the 200-day moving average is 13.18.

As of June 30, 2026, Vectorite Biomedical, Inc. holds 166.32M in cash and equivalents against 298,000.00 in total debt, resulting in a net debt position of -21.39M. Total book value stands at 510.66M, with working capital of 170.98M providing operational flexibility.

Vectorite Biomedical, Inc.'s most recent stock split took place on August 3, 2017 with a 991:1014 split ratio.